| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $7.40B | +6.6% |
| Cost of Revenue | $4.73B | +6.0% |
| R&D Expense | $236.1M | -0.2% |
| SG&A Expense | $757.1M | +8.6% |
| Operating Income | $1.91B | +7.3% |
| Pre-tax Income | $1.80B | +8.2% |
| Income Tax | $318.2M | +11.5% |
| Net Income | $1.48B | +7.6% |
| EPS (Basic) | $6.42 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $458.0M | +22.4% |
| Accounts Receivable | $1.12B | +18.0% |
| Inventory | $1.11B | +8.3% |
| Current Assets | $3.02B | +16.0% |
| Total Assets | $16.07B | +9.8% |
| Current Liabilities | $2.84B | +35.5% |
| Long-term Debt | $2.28B | +9.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.80B | -1.5% |
| Capital Expenditures | $130.2M | +2.5% |
| Investing Cash Flow | -$1.06B | -334.1% |
| Financing Cash Flow | -$686.3M | +57.2% |
| Free Cash Flow | $1.67B | -1.8% |
| +7.9% |
| EPS (Diluted) | $6.40 | +7.9% |
| Total Liabilities |
| $5.44B |
| +9.3% |
| Stockholders' Equity | $10.63B | +10.1% |